Dosing begins in Advaxis phase 1/2 study of Lovaxin C vaccine for cervical cancer

By Lisa Kerner

Erie, Pa., May 2 - The first cancer patients to be treated with an engineered live Listeria vaccine were dosed in Advaxis Inc.'s phase 1/2 clinical safety trial of Lovaxin C, a Listeria-based therapeutic cancer vaccine for cervical cancer.

A total of 20 cervical cancer patients will be enrolled in the six-month trial taking place in Serbia, Israel and Mexico.

Advaxis said this is its first human study in the development of cancer therapies using modified Listeria to deliver a tumor specific antigen to generate an immune response.

Based in North Brunswick, N.J., Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.